Kitazaki, Yuki published the artcilePrimary diffuse large B-cell lymphoma of the central nervous system with rapidly progressing lesions after dimethyl fumarate treatment, showing relapsing and remitting symptoms: A case report, Synthetic Route of 624-49-7, the publication is Clinical & Experimental Neuroimmunology (2022), 13(1), 60-65, database is CAplus.
Background : We present a case of B-cell type primary central nervous system lymphoma that rapidly progressed after di-Me fumarate (DMF) administration. Case presentation : An asymptomatic white matter lesion of the left frontal lobe was observed in a 56-yr-old Japanese man on magnetic resonance imaging during a medical checkup. For the subsequent 5 mo, the sporadic white matter lesion showed no change and no contrast effect. He suddenly presented with right upper limb paralysis on day 74. After improvement, he had a recurrence of right upper limb paralysis and diminished vision loss. Based on the 2017 revised McDonald criteria, two attacks, objective clin. evidence of one lesion and cerebrospinal fluid oligoclonal band assay positivity, he was diagnosed with relapsing-remitting multiple sclerosis and administered DMF. Three months after DMF administration, he developed new brain lesions that progressed rapidly; addnl. immunotherapy was ineffective. He was pathol. diagnosed with B-cell type primary central nervous system lymphoma using brain biopsy on day 301. Conclusion : Patients with rapidly progressing white matter lesions after DMF administration should be suspected for B-cell type primary central nervous system lymphoma and pathol. diagnosed using brain biopsy.
Clinical & Experimental Neuroimmunology published new progress about 624-49-7. 624-49-7 belongs to esters-buliding-blocks, auxiliary class Inhibitor,Natural product, name is Dimethyl fumarate, and the molecular formula is C6H8O4, Synthetic Route of 624-49-7.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics